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Abstract
Background Heart failure (HF) is associated with poor
prognosis, high morbidity and mortality. The progno-
sis can be optimised by guideline adherence, which
also can be used as a benchmark of quality of care.
The purpose of this study was to evaluate differences
in use of HF medication between Dutch HF clinics.
Methods The current analysis was part of a cross-
sectional registry of 10,910 chronic HF patients at
34 Dutch outpatient clinics in the period of 2013 until
2016 (CHECK-HF), and focused on the differences in
prescription rates between the participating clinics
in patients with heart failure with reduced ejection
fraction (HFrEF).
Results A total of 8,360 HFrEF patients were included
with a mean age of 72.3± 11.8 years (ranging be-
tween 69.1± 11.9 and 76.6± 10.0 between the clinics),
63.9% were men (ranging between 54.3 and 78.1%),
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27.3% were in New York Heart Association (NYHA)
class III/IV (ranging between 8.8 and 62.1%) and the
average estimated glomerular filtration rate (eGFR)
was 59.6± 24.6ml/min (ranging between 45.7± 23.5
and 97.1± 16.5).
The prescription rates ranged from 58.9–97.4%
for beta blockers (p<0.01), 61.9–97.1% for renin-an-
giotensin system (RAS) inhibitors (p<0.01), 29.9–86.8%
for mineralocorticoid receptor antagonists (MRAs)
(p< 0.01), 0.0–31.3% for ivabradine (p< 0.01) and
64.9–100.0% for diuretics (p<0.01). Also, the per-
centage of patients who received the target dose
differed significantly, 5.9–29.1% for beta blockers
(p< 0.01), 18.4–56.1% for RAS inhibitors (p< 0.01) and
13.2–60.6% for MRAs (p<0.01).
Conclusions The prescription rates and prescribed
dosages of guideline-recommended medication dif-
fered significantly between HF outpatient clinics in
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What’s new?
 In contemporary real-world practice, wide ranges
of demography, severity of heart failure and co-
morbidities of HFrEF patients were observed
between heart failure clinics in the Netherlands.
 The prescription rates and prescribed dosages
of guideline-recommended heart failure medi-
cation differed significantly between centres, not
fully explained by differences in patient profiles.
 In HFmrEF patients, overall use and doses of
heart failure medication, and ranges between
centres did not differ considerably from those in
HFrEF.
 Practical recommendations to improve heart
failure management in transmural networks are
provided.
the Netherlands, not fully explained by differences in
patient profiles.
Keywords Heart failure · HFrEF · HFmrEF ·
Guidelines · Adherence · Medication
Introduction
Heart failure (HF) is associated with a high symptom
burden, morbidity and mortality [1–3]. Optimis-
ing guideline-recommended HF therapies improve
health-related quality of life and prognosis [4–6].
However, in real-world practice, implementation and
adherence to recommended treatment, a benchmark
of quality of care, are suboptimal. A recent analysis
of medication profiles of 22,476 unselected patients
with a diagnosis of HF at hospital discharge between
2001 and 2015 derived from the Dutch PHARMO
Database Network showed only partial improvement
of prescribed HF medication over time [7]. The per-
centage of patients prescribed the combination of
a beta blocker and an angiotensin-converting-en-
zyme (ACE) inhibitor or angiotensin receptor blocker
increased from 24 to approximately 45% within this
15-year period. The percentage of patients who also
used a mineralocorticoid receptor antagonist (MRA)
reached approximately 20%. Notably, the probability
of being prescribed these combinations decreased
with increasing age and there was no significant in-
crease in MRA prescriptions. Moreover, recent real-
world registries demonstrated underuse of HF thera-
pies despite clear evidence-based recommendations
[8–10].
In fact, randomised clinical trials and surveys did
not represent real-life HF populations [11–13]. More-
over, the distribution of recommended HF treatment
and considerable practice variation between regions
and hospitals are largely unexplained, but also unex-
plored.
In a large-scale real-world registry at Dutch HF out-
patient clinics, we therefore investigated the differ-
ences in medical HF therapies and determinants of
prescription of individual, recommended HF drugs in
HFrEF patients [14, 15] among 34 HF clinics in the
Netherlands.
Methods
The design and methods of the CHECK-HF (Chronic
Heart failure ESC guideline-based Cardiology practice
Quality project) registry have been published in detail
earlier [14]. Briefly, the CHECK-HF registry consists of
10,910 patients with chronic HF from a total of 34 par-
ticipating centres (40% of the 86 centres in the Nether-
lands of which 60 have an outpatient HF unit) (Fig. 1).
Patients were included cross-sectionally based on the
available records of these patients. Between 2013 and
2016, all participating centres included patients diag-
nosed with HF based on the 2012 ESC guidelines on
HF (i.e. based on symptoms and echo parameters)
who were seen at the outpatient HF clinic (96%) or
general cardiology outpatient clinic (4%) if no specific
HF clinic was present.
Baseline patient characteristics, aetiology of HF,
comorbidities, basic echocardiographic and electro-
cardiographic (ECG) parameters, laboratory mark-
ers, pacemaker, implantable cardioverter-defibrilla-
tor treatment and cardiac resynchronisation therapy
as well as prescription rates of medication (drug
name, dosage and frequency and total daily dose)
were recorded. The target doses of guideline-rec-
ommended HF medication are presented in Suppl.
Table 1. Drug doses were calculated compared with
the recommended dose and according to guidelines as
a daily dose or %, percentage of actual recommended
daily dose.
Furthermore, contraindications and intolerance as
indicated by the treating physician were collected. No
predefined rules were applied to determine absolute
contraindications.
In 283 (2.6%) patients, recording of ejection fraction
in the database was insufficient to classify patients, so
these patients were excluded from this analysis.
Based on echocardiographic results, the remaining
10,627 patients were divided based on left ventric-
ular ejection fraction (LVEF) or visual assessment
of the function of the left ventricle into HF with
preserved ejection fraction (HFpEF) (LVEF ≥50%,
n= 2,267 (21%)) and HF with reduced ejection frac-
tion (HFrEF: LVEF <50%, n= 8,360 (79%)), according
to the 2012 ESC HF guidelines [4].
For a sub-analysis according to the newer 2016 ESC
HF guidelines, patients with an assessed LVEF <50%
were categorised into HF with mid-range ejection
fraction (HFmrEF) (LVEF 40–49%, n= 1,574 (19%)),
HFrEF (LVEF <40%, n= 5,701 (68%)), and into HF
with a semi-quantitative analysis of the systolic left
ventricular function only (n= 1,085 (13%)). In the
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current analyses, we focused on the prescribed HF
medication in HFrEF patients (LVEF <50%).
The Medical Research Ethics Committee of the
Maastricht University Medical Center, the Nether-
lands, provided ethical approval for anonymously
analysing existing patient data. No informed consent
of the participants in this registry was required.
Statistics
Continuous data are expressed as mean value±
standard deviation (SD) or median and interquartile
range, depending on the distribution of the data, and
compared by applying one-way analysis of variances
(ANOVA) or Mann-Whitney U test as appropriate.
Categorical data are expressed as counts and percent-
ages, and compared by the Pearson chi-squared test.
A two-sided p-value of 0.05 was considered statisti-
cally significant. Multivariable predictors for the use
of HF medication associated with the hospital-ranked
prescription of HF medication (beta blocker, renin-
Fig. 1 Geographical dis-
tribution of the 34 par-
ticipating clinics of the
CHECK-HF registry in the
Netherlands
angiotensin system [RAS] inhibitor, MRA, ivabradine
and diuretics, respectively) were sought, using multi-
variable logistic regression analysis, using the stepwise
forward procedure. All predictors of medication use
in univariable analysis at a p-value of <0.10 were
included in the multivariable regression analysis. Re-
sults of logistic regression are presented as odds ratios
(ORs) and confidence intervals (CIs).
All analyses were performed with SPSS Statistical
Package version 25.0 (SPSS Inc, Chicago, Illinois).
Results
Baseline characteristics of the total group of 8,360
HFrEF patients are shown in Table 1. Mean age
was 72.3± 11.8 years (ranging between 69.1± 11.9
and 76.6± 10.0 between the clinics), 63.9% were
men (ranging between 54.3 and 78.1%), 27.3% were
in New York Heart Association (NYHA) class III/IV
(ranging between 8.8 and 62.1%) and the aver-
age estimated glomerular filtration rate (eGFR) was
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59.6± 24.6ml/min (ranging between 45.7± 23.5 and
97.1± 16.5). Between centres, a wide range of preva-
lence rates with regard to ischaemic aetiology of HF,
atrial fibrillation and comorbidities were found, as
presented in Table 1. When subdividing HF patients
in LVEF groups according to ESC guidelines 2016,
HFmrEF patients (n= 1,574) were more often female,
had less often ischaemic aetiology, less wide QRS
complex and more often atrial fibrillation, hyper-
tension and chronic obstructive pulmonary disease
(COPD), all compared with HFrEF patients (n= 5,701).
However, in both groups, there was a wide variation
of all baseline characteristics between centres (Suppl.
Tables 2 and 3).
Guideline-recommended medical therapy in HFrEF
The prescription rates ranged between centres from
58.9–97.4% for beta blocker according to ESC guide-
lines 2012 (p<0.01), 61.9–97.1% for renin-angiotensin
system (RAS) inhibitors (p<0.01), 29.9–86.8% for
MRA (p<0.01), 0.0–31.3% for ivabradine (p<0.01) and
64.9–100.0% for diuretics (p<0.01), see Table 2 and
Fig. 2. In symptomatic HF patients (NYHA class II–IV),
guideline-recommended medication only slightly dif-
fered from the total HFrEF group (Suppl. Table 4).
Dual therapy (beta blocker and RAS inhibitor) was
prescribed in average 66.3% (min. 47.7 to max. 80.5)
of HFrEF patients, one out of two in 28.7% (15.6–43.7)
and none in 5.0% (0.9–13.5) respectively. Triple ther-
apy (beta blocker, RAS inhibitor and MRA) was pre-
scribed in average 35.6% (16.1–68.4) of HFrEF pa-
tients, two out of three in 45.7% (28.9–58.9), one out
of three in 16.1% (0.0–24.7) and none in 2.6% (0.0–6.9)
respectively. Also, the percentage of patients who re-
ceived the target dose differed significantly, 5.9–29.1%
for beta blocker (p<0.01), 18.4–56.1% for RAS in-
hibitor (p< 0.01) and 13.2–60.6% for MRA (p<0.01).
HFrEF patients seen at HF clinics received more
often beta blockers, MRA, ivabradine and diuretics in
comparison with those seen in general cardiology out-
patient clinics, although rates of prescribed of RAS
inhibitors were similar (Suppl. Table 5). Women with
HFrEF less often received RAS inhibitors (79% vs 83%),
but more often beta blockers (82% vs 79%) as com-
pared with men. MRA were given in 53% of patients,
both men and women (Suppl. Table 6).
Multivariable analysis of hospitals showed that the
differences in prescribed HFmedication between cen-
tres cannot be explained by clinical variables (Table 3,
see Suppl. Table 7 for univariable analysis).
According to ESC guidelines 2016, the prescription
rates in HF patients with LVEF <40%, both overall and
ranges between centres of prescription rates of HF
medication, were not different in a clinically mean-
ingful way from HF with LVEF <50%.
Table 1 Baseline characteristics of HFrEF patients (LVEF
<50%) and range between centres
Overall popula-
tion
Range
Number of patients 8,360 32; 1,549
Age (years) (n= 8,351) 72.27± 11.8 69.1± 11.9;
76.6± 10.0
Male gender (n= 8,323) 5,320 (63.9) 54.3; 78.1
BMI, kg/m2 (n= 7,671) 27.2± 5.2 26.2± 4.7; 28.4± 5.1
NYHA (n= 8,262)
– I 1,313 (15.9) 0.0; 45.5
– II 4,692 (56.8) 35.0; 88.1
– III 2,108 (25.5) 8.8; 60.0
– IV 149 (1.8) 0.0; 9.6
LVEF, % (n= 6,179) 32.6± 10.5 28.4± 10.5;
44.2± 16.0
Cause of HF (n= 8,094)
– Ischaemic cause of HF 4,182 (51.7) 34.9; 63.4
– Non-ischaemic cause of
HF
3,912 (48.3) 36.6; 65.1
Systolic BP, mmHg
(n= 8,246)
125.7± 20.7 113.8± 19.6;
135.4± 22.7
Diastolic BP, mmHg
(n= 8,252)
71.2± 11.4 64.9± 10.4;
75.1± 12.9
Heart rate, bpm (n= 8,248) 72.0± 13.9 64.7± 8.0;
76.7± 17.1
Atrial fibrillation (n= 8,253) 2,109 (25.6) 12.2; 50.0
LBBB (n= 8,360) 1,414 (16.9) 0.0; 30.2
QRS ≥130ms (n= 6,936) 2,774 (40.0) 0.0; 53.5
eGFR (n= 5,883) 59.6± 24.6 45.7± 23.5;
97.1± 16.5
eGFR (n= 5,883)
–<30 667 (11.3) 0.0; 27.3
– 30–59 2,442 (41.5) 0.0; 54.5
–≥60 2,774 (47.2) 18.2; 100.0
Comorbidity (n= 7,488)
– Hypertension 2,978 (39.8) 7.8; 75.5
– Diabetes Mellitus 2,174 (29.0) 16.7; 51.0
– COPD 1,381 (18.4) 9.5; 29.9
– OSAS 495 (6.6) 0.0; 14.1
– Thyroid disease 557 (7.4) 0.6; 11.8
– Renal insufficiencya 3,950 (56.3) 30.5; 78.9
– No relevant comorbidity 855 (13.6) 0.0; 28.3
aDefined as eGFR <60ml/min or a history of renal failure
BMI body mass index, NYHA New York Heart Association classifica-
tion, LVEF left ventricular ejection fraction, HF heart failure, HFrEF HF
with reduced ejection fraction, HFmrEF HF with mid-range ejection frac-
tion, HFpEF HF with preserved ejection fraction, BP blood pressure,
LBBB left bundle branch block, eGFR estimated glomerular filtration rate,
NT-proBNP N-terminal pro-brain natriuretic peptide, COPD chronic obstruc-
tive pulmonary disease, OSAS obstructive sleep apnoea syndrome
Medical treatment of HFmrEF and semi-quantitative
patients
The distribution of beta blockers, RAS inhibitors and
MRA in HFmrEF and semi-quantitative patients are
shown in Table 2. Both overall prescription rates and
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Table 2 Prescription rates of HF medication according to ESC Guidelines 2012 versus 2016 per participating clinic (n= 34)
Guideline-recommended pharmacotherapy (average % (min.–max.))
Beta blocker RAS inhibitor MRA Ivabradine Diuretics
ESC Guidelines 2012 HFrEF 80.1 (58.9–97.4) 81.2 (61.9–97.1) 53.0 (29.9–86.8) 4.6 (0.0–31.3) 82.8(64.9–100.0)
ESC Guidelines 2016 HFrEF 81.0 (63.6–96.0) 83.2 (65.3–97.4) 56.4 (34.1–88.0) 5.4 (0.0–31.0) 83.4 (65.4–100.0)
HFmrEF 77.7 (30.8–100.0) 76.8 (33.3–100.0) 45.1 (22.2–100.0) 3.1 (0.0–33.3) 79.5 (58.3–100.0)
HFsemiq 78.6 (0.0–100.0) 77.6 (0.0–100.0) 46.3(0.0–100.0) 2.5 (0.0–30.8) 84.8 (0.0–100.0)
HF heart failure, HFrEF HF with reduced ejection fraction, HFmrEF HF with mid-range ejection fraction, HFsemiq HF with semiquantitatively estimated left
ventricular ejection fraction—though <50%, ESC European Society of Cardiology, RAS renin-angiotensin system, MRA mineralocorticoid receptor antagonists
ranges between centres did not differ in a clinically
meaningful way from those in HFrEF patients. Also, in
all LVEF groups, there was a wide range of prescribed
dosages of HF medication percentages between cen-
tres (Suppl. Fig. 1, 2 and 3).
Discussion
From our outpatient HF registry in a representative
number of centres in the Netherlands, we demon-
strated that demography, HF characteristics and
comorbidities in HFrEF patients widely varied be-
tween those centres. Also, the prescription rates and
prescribed dosages of guideline-recommended HF
medication varied significantly, both for HFrEF and
HFmrEF patients. Those variations between hospi-
tals could not be explained by differences in baseline
characteristics of participating HF patients.
Overall, we found higher prescription rates of rec-
ommended HF medication than in previous registries,
which may be related to the delivery of specialist out-
patient HF care in the vast majority of patients [10].
Variation in prescribed heart failure medication
Remarkably, a wide distribution of prescribed medi-
cation between centres was observed. Many factors
may play a role both in suboptimal therapy in the
HF patients and in substantial variations between
centres. Previously we reported from CHECK-HF that
lower rates of guideline-directed pharmacotherapy
in HFrEF patients were associated with increasing
age, but much less influenced by comorbidities [10].
Recorded contraindications and intolerabilities did
not explain the underuse of RAS inhibitors, beta
blockers and MRA. Further analyses demonstrated
that elderly heart failure patients with reduced ejec-
tion fraction (≥75 years) were prescribed significantly
fewer beta blockers (77.8% vs 84.2%), RAS inhibitors
(75.2% vs 89.7%), MRAs (50.6% vs 59.6%) and ivabra-
dine (2.9% vs 9.3%), but significantly more diuretics
(88.1% vs 72.6%) compared with patients aged less
than 60 (P for all trends <0.01) [16]. In addition,
the prescribed target dosages were significantly lower
in elderly patients. Notably, patients with HFmrEF
showed a similar trend in use of medication as in
patients with HFrEF.
Also, recently reported data from the CHAMP-HF
registry with 3,518 participating patients from 150
primary care and cardiology practices, demonstrated
that lower medication utilisation or dose, was asso-
ciated with older age, lower blood pressure, more
severe functional class, renal insufficiency, and recent
HF hospitalisation [9].
Notably, only 40% of the total HFrEF cohort of the
Swedish Heart Failure Registry (11,215 patients, 27%
women; mean age 75± 11 years) received anMRA [17].
Underuse of MRA was not related to hyperkalaemia,
but it was, among other factors, related to impaired re-
nal function (even moderately impaired), which is not
a contraindication for MRA use. An explanation for
the underuse of MRA might be the reluctance of pre-
scribing an MRA to a vulnerable group of HF patients,
already treated with an RAS inhibitor, beta blocker
and in the majority of cases also a diuretic [18, 19].
Remarkably, age of patients in the present analysis
had no impact on the differences in prescription of
HF medication between centres.
Therefore, perceived polypharmacy, presence of co-
morbidities and overestimation of side-effects may in-
fluence use and dosing of evidence-basedmedication.
In addition, patient preferences and family caregiver
perceptions may influence therapeutic decisions [20].
Furthermore, an analysis by the BIOSTAT-CHF study
group suggested that women with HFrEF might need
lower doses of RAS inhibitors and beta blockers than
men, also adjusted for age [21].
However, it is unclear why not only new medica-
tion, e.g. ivabradine and more recently sacubitril/
valsartan, but also long-standing, established, dis-
ease-modifying therapies are not widely adopted nor
fully prescribed. Therefore, it is important to gain
detailed insights in reasons for not adopting recom-
mended therapies both at a hospital level and at an
individual patient level. Assessing information on
real motivation of medical decisions and perceived
barriers would contribute to effective improvement
of HF care.
Importantly, suboptimal use of HF medication may
have detrimental effects on clinical outcomes. Adher-
ence to guideline-directed therapy of HFrEF, with pre-
scription of at least 50% of the target dosage is asso-
ciated with better outcome [6, 22], at least in younger
patients with little comorbidities [23].
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Fig. 2 Prescription rates and prescribed dosages of HFmed-
ication in HFrEF patients (LVEF <50%) per participating clinic
(n= 34) (The left panels show the order of hospitals on the
x-axis based on the percentage of prescription rate of each
drug. The red bar is the overall presciption rate (%) and the
green bars are the prescription rates (%) in each clinic. The
same order is shown in the panels on the right.) (HF heart
failure, HFrEF heart failure with reduced ejection fraction,
LVEF left ventricular ejection fraction, RAS renin-angiotensin
system, MRA mineralocorticoid receptor antagonists)
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Table 3 Multivariable analysis of hospital differences in medical treatment of HFrEF patients (LVEF <50%)
Beta blocker RAS inhibitor MRA Ivabradine Diuretics
OR [95% CI] OR [95% CI] OR [95% CI] OR [95% CI] OR [95% CI]
Univariable Hospital 1.05 [1.04–1.05] 1.04 [1.04–1.04] 1.06 [1.06–1.06] 1.09 [1.08–1.10] 1.06 [1.06–1.06]
Multivariable Hospital 1.05 [1.04–1.06] 1.05 [1.04–1.06] 1.06 [1.05–1.07] 1.09 [1.07–1.10] 1.04 [1.03–1.05]
Gender 1.20 [1.02–1.40] – – – 1.31 [1.06–1.61]
Age (per 10 years) 0.83 [0.78–0.89] 0.79 [0.72–0.87] 0.87 [0.83–0.91] 0.61 [0.56–0.67] 1.14 [1.04–1.25]
BMI – 1.04 [1.02–1.06] 1.02 [1.01–1.03] – 1.06 [1.04–1.08]
Systolic BP (per 10mmHg) – – 0.84 [0.82–0.87] – 0.93 [0.87–1.00]
Diastolic BP (per 10mmHg) – – – 0.88 [0.79–0.98] 0.89 [0.80–1.00]
NYHA classification – 0.72 [0.63–0.82] 1.17 [1.08–1.27] 1.26 [1.05–1.50] 1.53 [1.30–1.80]
Heart rate (per 10 beats/min) – 0.84 [0.79–0.89] – – 1.12 [1.04–1.21]
QRS duration (per 10ms) – 0.97 [0.95–0.99] 1.04 [1.02–1.05] – 1.32 [1.01–1.72]
eGFR (per 10ml/min) – 1.06 [1.01–1.11] – –
Ischaemic aetiology – 0.76 [0.60–0.97] – –
Hypertension 1.22 [1.05–1.42] – – –
Diabetes mellitus II – – – 1.58 [1.21–2.08] 1.42 [1.11–1.81]
COPD – – – 1.58 [1.21–2.08] 1.32 [1.01–1.72]
Renal insufficiencya – – – – 2.50 [2.03–3.09]
– variable not included in the model
LVEF left ventricular ejection fraction, HF heart failure, HFrEF HF with reduced ejection fraction, OR odds ratio, CI confidence interval, RAS renin-angiotensin
system, MRA mineralocorticoid receptor antagonists, BMI body mass index, NYHA New York Heart Association, BP blood pressure, eGFR estimated glomerular
filtration rate, COPD chronic obstructive pulmonary disease
aDefined as eGFR <60ml/min or a history of renal failure
Optimising heart failure management
Although nonadherence to guideline-directed HF
therapies is not fully understood, several practical
recommendations to improve HF management can
be made (Suppl. Table 8).
Obviously, being informed on performance of
health care professionals involved in HF manage-
ment, will contribute to improving delivery of care.
Therefore, the CHECK-HF centres received individual
feedback and in national meetings possible solutions
to optimise HF care were shared. Furthermore, a na-
tionwide, structured HF registry is being launched.
Acknowledging that HF care should be delivered
seamless to patients, the Netherlands Society of Car-
diology, started the CONNECT Heart Failure pro-
gramme, in which concepts of integrated collabora-
tion were translated towards detailed protocols by
joint health care professionals in geographic regions
[24]. These collaborations also provide strategies for
optimising diagnostic pathways and HF therapies, ac-
companied by educational activities for professional
teams. The initiated national registry will provide in-
formation on the effectiveness of incorporating these
strategies.
At a patient level, clinical judgment of the heart
failure syndrome, management of comorbidities, in
concert with optimally implemented disease-modify-
ing therapies are of pivotal importance [25–27]. In
addition, blood pressure, renal function and hyper-
kalaemia may limit up-titration of all recommended
drugs [28]. This may be evenmore complicated by the
fact that the number of drug classes shown to improve
outcome in HFrEF is increasing [29]. Among potential
solutions are start-low and go-slow dosing strategies,
close monitoring of vital parameters and side-effects,
the use of new potassium binders and angiotensin
receptor/neprilysin inhibition. Critical appraisal and
reduction of co-medication may also be beneficial. In
addition, pharmacy care improves adherence to HF
medications and quality of life, which was recently
demonstrated by the PHARM-CHF investigators [30].
In concert with dedicated efforts of professional HF
teams, well-informed patients and family caregivers
may empower their participation in medical decision-
making and contributes to earlier access of new ther-
apies [5, 24]. Informed treatment choices are of par-
ticular relevance in guidance of decisions during ad-
vanced and palliative stages of care.
Limitations and strenghts
The CHECK-HF registry is a large-scale real-world reg-
istry of HF outpatient clinics in the Netherlands reflec-
tive of Western European countries. However, some
limitations should be mentioned, such as the cross-
sectional design limiting follow-up data on patient
outcomes. Some missing data exists, which might in-
fluence results. Our registry included only patients
seen in secondary, but not in primary care, which lim-
its the generalisability of our findings to the primary
care setting. Information on actual protocols of di-
agnostic workup and medical decision-making strate-
gies in centres was not collected. Notably, the CHECK-
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HF inclusion period was from 2013 till end of 2016, in
which the CONNECT programme for Heart failure re-
gional care had been in the initial phase of implemen-
tation in regions. Therefore, we have not collected
data on adoption of the CONNECT Heart Failure pro-
gramme in the centres. Strengths of the study are the
reflection of the true practice of large scale nationwide
outpatient HFmanagement with detailed information
on medication prescription and dosage.
Conclusion
In this Dutch real-world registry of outpatient HF
population, wide between-clinic ranges of demogra-
phy, severity of heart failure and comorbidities of HF
patients were observed. Also the prescription rates
and prescribed dosages of guideline-recommended
HF medication differed significantly, not fully ex-
plained by differences in the patient profiles. Thus,
future research should lead to strategies to improve
management of HF patients including reduction of
practice variation.
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